A61K 38/4813
Exopeptidases
Official title: {Exopeptidases (3.4.11. to 3.4.19)}
A61K38/4813 (Exopeptidases) appears on 130 US grants and 284 published applications in this corpus.
Search patents in A61K- Granted patents
- 130
- Published applications
- 284
- Assignees
- 158
- Inventors
- 473
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 3 | 1 |
| 2002 | 3 | 2 |
| 2003 | 5 | 14 |
| 2004 | 3 | 3 |
| 2005 | 5 | 12 |
| 2006 | 2 | 9 |
| 2007 | 2 | 9 |
| 2008 | 6 | 11 |
| 2009 | 3 | 7 |
| 2010 | 5 | 11 |
| 2011 | 11 | 12 |
| 2012 | 5 | 9 |
| 2013 | 5 | 11 |
| 2014 | 4 | 9 |
| 2015 | 4 | 8 |
| 2016 | 5 | 15 |
| 2017 | 8 | 9 |
| 2018 | 7 | 11 |
| 2019 | 7 | 16 |
| 2020 | 7 | 7 |
| 2021 | 4 | 11 |
| 2022 | 3 | 25 |
| 2023 | 5 | 22 |
| 2024 | 8 | 20 |
| 2025 | 1 | 9 |
| 2026 | 5 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- ACE2 muteins and methods of using the same7 Jul 2026US 12,674,153 B2Emmune, Inc.
- Targeting peptides for directing adeno-associated viruses (AAVs)16 Jun 2026US 12,653,904 B2California Institute of Technology
- Probiotic compositions for treating and preventing colorectal cancer26 May 2026US 12,636,325 B2The Chinese University of Hong Kong
- Methods of treating dementia associated with alzheimer's disease with protective protein/cathepsin A (PPCA)26 May 2026US 12,640,251 B2St. Jude Children?S Research Hospital
- Compositions and methods for treating bone injury10 Feb 2026US 12,544,404 B2Board of Regents, The University of Texas System
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Modulation of pd-1 signaling for treatment of diseases30 Jul 2026US 2026/0216168 A1Wuhan University
- Novel gene therapy construct for cln2 disease30 Jul 2026US 2026/0216378 A1The Children’s Hospital of Philadelphia
- Use of carboxypeptidase e/neurotrophic factor-alpha1 to treat neurodegenerative disease16 Jul 2026US 2026/0199441 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Proteins with minimal n-terminal initiator methionine9 Jul 2026US 2026/0193662 A1Unichem Laboratories Ltd
Most cited
By later US patents
- Recombinant AAV capsid protein95US 9,585,971 B2California Institute of Technology · 2017
- Compositions and methods relating to reduction of symptoms of autism63US 6,899,876 B2Prothera, Inc. · 2005
- Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase63US 7,899,527 B2Palo Alto Investors · 2011
- Compositions and methods relating to reduction of symptoms of autism62US 6,821,514 B2Prothera, Inc. · 2004
- Compositions and methods relating to reduction of symptoms of autism57US 6,808,708 B2Prothera, Inc. · 2004